Zacks Investment Research
05 Jan 2026, 18:00 UTC · 38w ago
Verdict
Source says Upgrade to Buy. We score VVOS +1.00 across two claims.
Score confirms the headline.
Upgrade to Buy
Rating stated in the headline
+1.00strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Vivos Therapeutics (VVOS) was upgraded to a Zacks Rank #2 (Buy).
More positive than 66% of claims this week
The Zacks upgrade for Vivos Therapeutics was triggered by an upward trend in earnings estimates.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company was upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
7h ago
−94.7%
Price is moving against the score
$0.1337 vs $2.53 close before publication (Jan 2) · not market-adjusted
VVOS chart →
